PTGX vs SIBN: fair value comparison
Protagonist Therapeutics, Inc. and SI-BONE, Inc. · Updated 2026-10-19
PTGX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. SIBN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PTGX currently ranks higher by quality score.
| PTGX | SIBN | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $128.75 | $19.68 |
| 12-month range | $73.98–$158.62 | $11.61–$21.40 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #88 of 301 Healthcare | #89 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: PTGX fair value analysis · SIBN fair value analysis